Cartesian Therapeutics Inc
RNAC7.550USD
-0.120-1.56%
Fechamento 11/06, 16:00（ET）Cotações atrasadas em 15 min
196.30MValor de mercado
PerdaP/L TTM
Mais detalhes de Cartesian Therapeutics Inc Empresa
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Informações de Cartesian Therapeutics Inc
Código da empresaRNAC
Nome da EmpresaCartesian Therapeutics Inc
Data de listagemJun 22, 2016
CEODr. Carsten Brunn, Ph.D.
Número de funcionários66
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 22
Endereço7495 New Horizon Way
CidadeFREDERICK
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal21703
Telefone13013488698
Sitehttps://www.cartesiantherapeutics.com/
Código da empresaRNAC
Data de listagemJun 22, 2016
CEODr. Carsten Brunn, Ph.D.
Executivos da empresa Cartesian Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Lead Independent Director
Lead Independent Director
3.82K
-14.03%
Dr. Kemal Malik
Dr. Kemal Malik
Independent Director
Independent Director
--
-100.00%
Dr. Michael S. Singer, M.D., Ph.D.
Dr. Michael S. Singer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Timothy C. (Tim) Barabe
Mr. Timothy C. (Tim) Barabe
Independent Director
Independent Director
--
--
Dr. Nishan M. de Silva, M.D.
Dr. Nishan M. de Silva, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Lead Independent Director
Lead Independent Director
3.82K
-14.03%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 14 de ago
Atualizado em: qui, 14 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Springer Timothy A
33.22%
Seven One Eight Three Four Irrevocable Trust
17.52%
Fidelity Management & Research Company LLC
8.98%
Singer (Michael S.)
2.72%
MPM BioImpact LLC
2.64%
Outro
34.93%
Investidores
Investidores
Proporção
Springer Timothy A
33.22%
Seven One Eight Three Four Irrevocable Trust
17.52%
Fidelity Management & Research Company LLC
8.98%
Singer (Michael S.)
2.72%
MPM BioImpact LLC
2.64%
Outro
34.93%
Tipos de investidores
Investidores
Proporção
Individual Investor
39.87%
Corporation
20.04%
Investment Advisor
17.88%
Investment Advisor/Hedge Fund
5.51%
Hedge Fund
1.66%
Research Firm
0.24%
Insurance Company
0.08%
Bank and Trust
0.05%
Pension Fund
0.03%
Outro
14.64%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
181
6.62M
25.45%
-1.00M
2025Q2
206
22.27M
85.81%
-1.28M
2025Q1
226
22.94M
90.08%
+138.68K
2024Q4
230
22.26M
88.90%
-105.22K
2024Q3
229
20.22M
92.77%
+6.58M
2024Q2
235
14.41M
85.20%
+9.02M
2024Q1
233
3.74M
346.71%
-1.42M
2023Q4
240
3.82M
71.00%
-922.87K
2023Q3
251
3.63M
70.60%
-1.17M
2023Q2
261
3.72M
72.70%
-649.68K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Springer Timothy A
8.64M
33.22%
+22.36K
+0.26%
Apr 14, 2025
Seven One Eight Three Four Irrevocable Trust
4.56M
17.52%
--
--
Apr 14, 2025
Fidelity Management & Research Company LLC
2.33M
8.98%
-5.79K
-0.25%
Jun 30, 2025
Singer (Michael S.)
707.06K
2.72%
-623.00
-0.09%
Apr 14, 2025
MPM BioImpact LLC
686.01K
2.64%
-104.77K
-13.25%
Jun 30, 2025
TAS Partners, L.L.C.
656.51K
2.52%
+126.72K
+23.92%
Apr 14, 2025
BlackRock Institutional Trust Company, N.A.
582.03K
2.24%
-26.00K
-4.28%
Jun 30, 2025
Invus Public Equities Advisors, LLC
563.27K
2.17%
--
--
Jun 30, 2025
Kalayoglu (Murat)
502.42K
1.93%
-8.88K
-1.74%
Apr 14, 2025
The Vanguard Group, Inc.
496.37K
1.91%
-7.17K
-1.42%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: há 23 horas
Atualizado em: há 23 horas
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Biotechnology ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Proshares Ultra Russell 2000
0%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.72%
Invesco Nasdaq Biotechnology ETF
Proporção0.03%
ProShares Ultra Nasdaq Biotechnology
Proporção0.03%
iShares Micro-Cap ETF
Proporção0.02%
iShares Russell 2000 Value ETF
Proporção0.01%
iShares Biotechnology ETF
Proporção0.01%
ALPS Medical Breakthroughs ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Data
Tipo
Proporção
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
